Clinical Trials Directory

Trials / Unknown

UnknownNCT02490020

A Perspective Multicenter Controlled Study On Application Of Mesenchymal Stem Cell(MSC) To Prevent Rejection After Renal Transplantation By Donation After Cardiac Death

Status
Unknown
Phase
Phase 1
Study type
Interventional
Enrollment
260 (estimated)
Sponsor
Qipeng Sun · Academic / Other
Sex
All
Age
18 Years – 60 Years
Healthy volunteers
Not accepted

Summary

Although donation after cardiac death(DCD) is the major source of renal transplantation in China, high incidence rate of rejection and delayed graft function(DGF) is existing due to the prolonged ischemia time. According to the previous single center study, mesenchymal stem cell (MSC) had an effect to prevent rejection and DGF after renal transplantation, but there was no perspective multicenter controlled study to confirm it. This perspective multicenter controlled study will focus on clarifying the key role of MSC applied via renal arterial or peripheral vein injection, to reduce the rejection and DGF after renal transplantation. The investigators have established GMP workshop and solid research foundation of transplant rejection. This study will provide a new reasonable way for immune induction of renal transplantation by DCD.

Conditions

Interventions

TypeNameDescription
BIOLOGICALmesenchymal stem cell

Timeline

Start date
2016-01-01
Primary completion
2016-12-01
Completion
2018-12-01
First posted
2015-07-03
Last updated
2015-07-03

Source: ClinicalTrials.gov record NCT02490020. Inclusion in this directory is not an endorsement.